Arcutis director plans $114K stock sale

Director Howard Welgus filed a Rule 144 notice to sell 4,730 ARQT common shares valued at about $114,000.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) is the issuer for which director Howard Welgus has filed a notice of proposed sales under Rule 144. The filing covers the planned sale of 4,730 shares of common stock, with an aggregate market value of $114,371.40, through a brokerage firm on NASDAQ.

Key Figures

Shares proposed to be sold: 4,730 shares Aggregate market value of proposed sale: $114,371.40 Shares outstanding: 125,691,961 shares +5 more

8 metrics

Shares proposed to be sold 4,730 shares Common stock covered by the Rule 144 notice

Aggregate market value of proposed sale $114,371.40 Value of 4,730 shares of common stock

Shares outstanding 125,691,961 shares Common stock of Arcutis Biotherapeutics as stated in the notice

Shares sold on June 17, 2026 635 shares Past 3 months sales reported for Howard Welgus

Proceeds on June 17, 2026 sale $16,300.45 Sale of 635 shares of common stock

Shares sold on July 15, 2026 4,730 shares Past 3 months sales reported for Howard Welgus

Proceeds on July 15, 2026 sale $127,284.30 Sale of 4,730 shares of common stock

Proceeds on August 17, 2026 sale $123,834.71 Sale of 4,730 shares of common stock

Key Terms

Rule 144, Restricted Stock Vesting, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 06/04/2026 | Restricted Stock Vesting | Arcutis Biotherapeutics"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Stock Option Exercise financial

"Common | 11/20/2019 | Stock Option Exercise | Arcutis Biotherapeutics"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Arcutis Biotherapeutics (ARQT)?

The filing discloses that director Howard Welgus plans to sell 4,730 shares of Arcutis Biotherapeutics common stock under Rule 144, with an aggregate market value of $114,371.40, to be sold through a brokerage firm on NASDAQ.

How many ARQT shares are covered by the new Rule 144 sale notice?

The notice covers a proposed sale of 4,730 shares of Arcutis Biotherapeutics common stock. These shares arise from restricted stock vesting and multiple stock option exercises on various grant dates.

What is the market value of the ARQT shares to be sold under this Form 144?

The Form 144 states an aggregate market value of $114,371.40 for the 4,730 shares of Arcutis Biotherapeutics common stock proposed to be sold.

What prior ARQT share sales by Howard Welgus are reported in the last three months?

The filing reports sales of 635 shares for $16,300.45 on June 17, 2026, 4,730 shares for $127,284.30 on July 15, 2026, and 4,730 shares for $123,834.71 on August 17, 2026.

How many Arcutis Biotherapeutics shares are outstanding according to the Form 144?

The filing lists 125,691,961 shares of Arcutis Biotherapeutics common stock as outstanding, providing context for the 4,730 shares covered by the proposed Rule 144 sale notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:04 PM Accepted by SEC EDGAR 09/15/2026 - 04:03 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4730	114371.4	125691961	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			634	06/04/2026	NA
Common	11/20/2019	Stock Option Exercise	Arcutis Biotherapeutics			822	09/15/2026	Cash
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1019	09/15/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			2255	09/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	06/17/2026	635	16300.45
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/15/2026	4730	127284.3
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	08/17/2026	4730	123834.71

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)